Shukra Pharmaceuticals Limited SHUKRAPHAR NSEPHARMA
Company Overview
Shukra Pharmaceuticals Limited engages in the manufacturing, marketing, and export of pharmaceutical formulations in India and internationally. The company offers various products, such as antibiotics, anti biotics, macrolides, quinolones, anti bacterial, anti fungal, anti malarial, anti viral, anti protozoal, anti anthelmintic, sedative and tranquilliser, anti depressant, anti manic, anti emetic, anti ulcer, beta blockers, diuretics, analgesic, muscle relaxants, anti tuberculosis, vitamin products, anti allergics, corticosteroids, hyper and hypoglycemic, and other products. It provides its products in ampoules, capsules, vials, and tablet forms. In addition, the company provides laboratory services; and surgical robots, diabetes technologies, cardiac sciences, advanced surgical and diagnostic solutions, imaging and critical care, medical simulations, wound care, boron neutron capture therapy, and virtual autopsy and forensic sciences. Further, it is involved in the supplying, selling, and distributing medical consumables; offers wound care products, medical, surgical, healthcare devices, materials, consumables, and allied solutions, as well as diabetes-related medical technologies solutions; and provision of virtual autopsy services and solutions. Additionally, the company offers expendable and non-expendable medical products, medical devices, emergency healthcare systems, combat medical support systems, first aid kits, trauma care kits; and artificial intelligence (AI), machine learning, deep learning, data analytics, predictive analytics, computer vision, natural language processing, generative AI, robotics, automation, digital platforms, hardware, cloud-based systems, decision support systems, and other technology solutions. The company was formerly known as Relish Pharmaceuticals Limited and changed its name to Shukra Pharmaceuticals Limited in August 2016. Shukra Pharmaceuticals Limited was incorporated in 1993 and is headquartered in Ahmedabad, India.
Why Investors Should Care
Generates a return on equity of 24.6%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 31.7%.
Net profit has compounded at 71.1% per year over the last five years.
Maintains a net profit margin of 45.4%.
Carries low leverage with a debt-to-equity ratio of 0.06.
Recent Developments
- Mar 2026 Revenue of ₹56.73 Cr (+74.1% YoY); net profit ₹22.06 Cr.
- Trailing 12 Months Year-on-year growth — revenue +336.3%, earnings +1400.0%.
- 5-Year Trend Long-term compounding — revenue CAGR -1.2%, profit CAGR 71.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -1.21% |
| 1 Year: | 336.30% |
Compounded Profit Growth
| 5 Years: | 71.06% |
| 1 Year: | 1,400.00% |
Stock Price Performance
| 1 Year: | +65.07% |
| 6 Months: | - |
| 3 Months: | - |
| 1 Month: | +23.55% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- RSI (14)68.42 · Neutral
P/E of 87.64 is above the sector median of 36.43 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 24.6%.
- Healthy ROCE of 31.7%.
- Excellent profit margin of 45.4%.
- Profit CAGR of 71.1% over 5 years.
CONS
- Trading at a high P/E of 87.6.
- Revenue declined at -1.2% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SHUKRAPHAR Shukra Pharmaceuticals Limited NSEPHARMA | 68.36 | 87.64 | ₹3,013.22 Cr | 0.02% | 31.67% | 24.55% | -1.21% | 71.06% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,745.10 | 34.62 | ₹4.19 L Cr | 0.91% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 9,190.00 | 83.58 | ₹2.44 L Cr | 0.32% | 18.96% | 15.32% | 10.98% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,553.80 | 72.74 | ₹1.73 L Cr | 0.81% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,117.30 | 24.90 | ₹1.11 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 6 | LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA | 631.35 | 164.41 | ₹1.09 L Cr | 0.00% | 7.21% | 5.65% | 35.38% | 66.99% |
| 7 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 7,600.00 | 52.32 | ₹1.09 L Cr | 0.25% | 19.20% | 20.48% | 14.85% | 33.34% |
| 8 | LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA | 2,012.50 | 99.48 | ₹1.09 L Cr | 0.12% | 19.53% | 16.77% | 3.77% | 4.00% |
| 9 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,314.00 | 31.51 | ₹1.06 L Cr | 0.99% | 14.86% | 11.27% | 7.23% | 11.45% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 13.27 Cr | 5.39 Cr | 5.88 Cr | 39.13 Cr | 6.32 Cr |
| Cost of Revenue | - | 1.76 Cr | 77.03 L | 2.00 Cr | 7.13 Cr | 5.94 Cr |
| Gross Profit | - | 11.51 Cr | 4.62 Cr | 3.87 Cr | 32.00 Cr | 38.38 L |
| Operating Expenses | - | 5.13 Cr | 4.09 Cr | 5.10 Cr | 5.70 Cr | 69.12 L |
| Operating Income | - | 6.38 Cr | 53.16 L | -1.23 Cr | 26.30 Cr | -30.74 L |
| EBITDA | - | 8.78 Cr | 2.43 Cr | 1.29 Cr | 27.95 Cr | 1.65 Cr |
| Interest Expense | - | 27.08 L | 26.81 L | 28.50 L | 28.17 L | 25.83 L |
| Pretax Income | - | 7.57 Cr | 1.37 Cr | 19.84 L | 26.83 Cr | 38.15 L |
| Tax Provision | - | 2.18 Cr | 34.35 L | -2.18 Cr | 6.47 Cr | 2.10 Cr |
| Net Income | - | 5.39 Cr | 1.03 Cr | 2.38 Cr | 20.36 Cr | -1.72 Cr |
| Diluted EPS | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 58.83 Cr | 74.57 Cr | 32.59 Cr | 56.73 Cr |
| Cost of Revenue | - | 45.32 Cr | 44.49 Cr | 8.11 Cr | 15.85 Cr |
| Gross Profit | - | 13.52 Cr | 30.09 Cr | 24.48 Cr | 40.88 Cr |
| Operating Expenses | - | 9.99 Cr | 12.73 Cr | 14.75 Cr | 15.58 Cr |
| Operating Income | - | 3.53 Cr | 17.35 Cr | 9.72 Cr | 25.30 Cr |
| EBITDA | - | 6.53 Cr | 22.21 Cr | 16.94 Cr | 33.32 Cr |
| Interest Expense | - | 25.56 L | 27.63 L | 59.49 L | 1.09 Cr |
| Pretax Income | - | 4.44 Cr | 19.88 Cr | 13.34 Cr | 28.79 Cr |
| Tax Provision | - | 3.52 L | 1.35 Cr | 3.76 Cr | 6.73 Cr |
| Net Income | - | 4.41 Cr | 18.54 Cr | 9.58 Cr | 22.06 Cr |
| Diluted EPS | 0.02 | 0.14 | 0.42 | 0.22 | - |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 74.97 Cr | 77.84 Cr | 86.77 Cr | 117.44 Cr |
| Current Assets | - | 53.07 Cr | 56.23 Cr | 65.43 Cr | 83.81 Cr |
| Cash & Equivalents | - | 3.97 Cr | 9.98 Cr | 12.12 Cr | 5.98 Cr |
| Inventory | - | 3.16 Cr | 2.31 Cr | 9.95 Cr | 13.90 Cr |
| Receivables | - | 30.19 Cr | 24.51 Cr | 8.77 Cr | 22.95 Cr |
| Total Liabilities | - | 49.67 Cr | 20.20 Cr | 23.93 Cr | 27.59 Cr |
| Current Liabilities | - | 42.51 Cr | 14.15 Cr | 17.28 Cr | 23.09 Cr |
| Long Term Debt | - | 3.77 Cr | 2.66 Cr | 3.11 Cr | 3.19 Cr |
| Total Debt | - | 5.08 Cr | 3.15 Cr | 4.18 Cr | 5.02 Cr |
| Total Equity | - | 25.30 Cr | 57.63 Cr | 62.84 Cr | 89.85 Cr |
| Shares Outstanding | - | 7.20 Cr | 43.79 Cr | 43.79 Cr | 43.79 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 3.17 Cr | -5.20 Cr | 7.92 Cr | 3.93 Cr |
| Investing Cash Flow | - | -4.43 Cr | -1.20 Cr | -1.26 Cr | -14.14 Cr |
| Financing Cash Flow | - | 4.94 Cr | 12.40 Cr | -4.52 Cr | 4.07 Cr |
| Capital Expenditure | - | -4.49 Cr | -1.76 Cr | -2.74 Cr | -15.73 Cr |
| Free Cash Flow | - | -1.32 Cr | -6.96 Cr | 5.18 Cr | -11.80 Cr |
| Net Change in Cash | - | 3.68 Cr | 6.01 Cr | 2.14 Cr | -6.14 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 23.0% | 40.3% | 75.1% | 72.1% |
| Operating Margin % | - | 6.0% | 23.3% | 29.8% | 44.6% |
| Net Margin % | - | 7.5% | 24.9% | 29.4% | 38.9% |
| ROE % | - | 17.4% | 32.2% | 15.2% | 24.6% |
| ROCE % | - | 10.9% | 27.2% | 14.0% | 26.8% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SHUKRAPHAR
SHUKRA MEDTECH (NSEI:SHUKRAPHAR) - Stock Analysis - Simply Wall Street
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxNTFNBSkdCak91a1ltNWQzNjNCaENMN3VaNFExVVl0S0Z4c1RSSHM2SU9wenNrMWF2ZURyOEdlclQ4dVBuV1hOS3hDUVJlY3h4d2U1SU5xVEl1RUpmTm9vb2ZsRkxlRnhoS05XRXl1alZqVHVNMkc0a256SENQZ05kVzBLVlJpeGFtYjYydF…
SHUKRAPHAR Stock Price and Chart — NSE:SHUKRAPHAR - TradingView
<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTE9uQWhJbG50UEVvdkFiVnpVbVFtWHFPb0RtZjFXOURMblZwd25TT1NmYmN1OFdlcjR1b3k3elZQNnVLTElVekF3dGJqLUVmNUNOTlVtQ0NBYzhUem5KSHlXaw?oc=5" target="_blank">SHUKRAPHAR Stock Price and Chart — NS…
SHUKRA MEDTECH LIMITED (SHUKRAPHAR) Company Information - Simply Wall Street
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxQS2lTckN6dXpFTjJhak5sd0FBbXZHbEVWMnlFZGdESVhLWDkzVngxX0RIbjhfcDNFd2REbjdqbVg1ZjFhUjAtMDV0dVpKWUE3V2E3S0thT09TY1VjSDFSQVN4TTJ1Uk5scFpGR1hwSFppNmRtTDBhODRBLVhxVDR3enA2bTBpRXhBMmVnd2…
SHUKRAPHAR Share Price Today - Shukra Pharmaceuticals Stock Analysis - Equitypandit
<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTE96NmdVbmlqVlQtVDR3aENLZlFveks4dXZFbU5zajZvbjlaVEJFYlBzN09CbVVkWGlMdjNlYnl5Rm5nN3lRS2dRenBJMFhxUmtlRXdQS1JhNWplNWNSMVBCbg?oc=5" target="_blank">SHUKRAPHAR Share Price Today - Shukra…
Technical Analysis of Shukra Pharmaceuticals Ltd. (NSE:SHUKRAPHAR) - TradingView
<a href="https://news.google.com/rss/articles/CBMib0FVX3lxTE1fZlU0VFJBTldFUHN4amZac1h6NFYyVDZDRUpBNWdLb1NxRW90a3ZSS0dmNDF4UUpGcGpINGZ1RnhBTlV2b1JmVHcwMzJ5SVhWb0JZaXcwaFBJZVg5cERYWTgxOHJhUjVfeFlvLUVYOA?oc=5" target="_blank">Technical Analysi…
SHUKRA MEDTECH LIMITED (SHUKRAPHAR.BO) Stock Price, News, Quote & History - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiXkFVX3lxTE52cE9UVEYwTzFGN0ZDMlJXNVNhMEZHd2hSLTFQeExQeHpMVTNFbjl6ck82TzRKVHRPOU5XeUMtNlpNQkxhNk1hd09xS3lIcEhSZ193aEd5M0lWeUZHbGc?oc=5" target="_blank">SHUKRA MEDTECH LIMITED (SHUKRAPHAR.BO) S…
SHUKRAPHAR — Frequently Asked Questions
What is the current share price of Shukra Pharmaceuticals Limited (SHUKRAPHAR)?
As of 2026-10-23 04:58 IST, Shukra Pharmaceuticals Limited (SHUKRAPHAR) trades at ₹68.36 on NSE. Its 52-week range is ₹41.41 to ₹72.58.
What is the market capitalisation of SHUKRAPHAR?
Shukra Pharmaceuticals Limited (SHUKRAPHAR) has a market capitalisation of ₹3,013.22 Cr on NSE.
What is the P/E ratio of SHUKRAPHAR?
SHUKRAPHAR trades at a trailing price-to-earnings (P/E) ratio of 87.64. The industry average P/E is 36.43. Its price-to-book (P/B) ratio is 26.71.
Does SHUKRAPHAR pay a dividend?
Shukra Pharmaceuticals Limited (SHUKRAPHAR) currently offers a dividend yield of 0.02%.
What is the return on equity (ROE) of SHUKRAPHAR?
SHUKRAPHAR has a return on equity (ROE) of 24.55%. Its return on capital employed (ROCE) is 31.67%.
Is SHUKRAPHAR a good stock to buy?
This page provides a data-driven analysis of Shukra Pharmaceuticals Limited (SHUKRAPHAR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.